Correlação da dosagem de glicose por glicosímetro, dosagem laboratorial e de equipamento de inteligência artificial
Gabriel Garcia Oliveira; Romulo Pillon Barcelos; Luciano de Oliveira Siqueira
University of Passo Fundo, Institute of Biological Sciences, Passo Fundo, RS, Brazil..
Introduction: With the increasing number of cases related to Diabetes Mellitus (DM), glycemic control through laboratory methods or rapid tests is essential.
Objective: To analyze the correlation of three glucose determination methodologies (Glucometer, laboratory analysis and with point of care artificial intelligence equipment).
Method: Blood samples from the digital pulp and venous blood from the antecubital fossa were collected from 20 volunteers of different ages and sex. Blood glucose measurements were determined by the 3 methodologies mentioned above.
Result: Spearmans correlation analysis carried out between all types of tests shows that there is a strong and statistically significant positive correlation, indicating the compatibility of results regardless of the method applied.
Conclusion: The methodologies are correlated, however, the average values?? obtained by artificial intelligence were 40% higher, which can impact the clinical interpretation of results.
Key words: diabetes mellitus; artificial intelligence; blood glucose self-monitoring; blood glucose..
Introdução: Com o número crescente de casos relacionados a Diabetes Mellitus (DM), é indispensável o controle glicêmico através de métodos laboratoriais ou testes rápidos.
Objetivo: Analisar a correlação de três metodologias de determinação de glicose (Glicosímetro, análise laboratorial e com o equipamento com inteligência artificial de point of care).
Método: Foram coletadas amostras de sangue da polpa digital e sangue venoso da fossa antecubital de 20 voluntários de diferentes idades e sexo. Dosagens de glicose sanguínea foram determinadas pelas 3 metodologias acima citadas.
Resultado: A análise de correlação de Spearman realizada entre todos os tipos de testes mostra que há uma correlação positiva forte e estatisticamente significante, indicando a compatibilidade de resultados independentemente do método aplicado.
Conclusão: As metodologias apresentam correlação, no entanto, os valores médios obtidos pela inteligência artificial mostraram-se 40% mais elevada que pode impactar na interpretação clínica dos resultados.
Palavras-chave: diabetes mellitus; inteligência artificial; glicemia; Automonitorização da Glicemia.
Diabetes mellitus (DM) is a highly prevalent disease that affects a large number of people worldwide. In Brazil there are approximately 5 million confirmed cases(1-3), but even with guidance and the availability of information, it is a subject that still raises doubts and a difficult treatment effectiveness, as patients with diabetes mellitus must adapt their lifestyle to live in the best possible way with this disease through changes in eating habits, physical exercise, use of medication and, in some cases, the use of insulin(4-7).
Prevention and delay of chronic complications are achieved through glycemic control and therapeutic adherence(8-10), and for that, it is necessary to regularly measure glucose levels through rapid tests, known as hemoglycotest (HGT), normally marketed in pharmacies, or with laboratory tests (performed in conjunction with other routine tests(11-13).
However, the cost, quality and handling is different for each point of care equipment. These technological differences can cause uncertainty in the interpretation of blood glucose results by patients, physicians and caregivers. Glucose determination using the “point-of-care” technology in pharmacies has emerged as another alternative for offering quick, cheap and accessible tests to the population(14,11).
The glucometer is a rapid glucose test device, an easily accessible and very practical device, as it is possible to measure at home with just one drop of blood, widely used by diabetics to control blood glucose(15,16). However, there are differences in the accuracy of this device compared to tests. (Roche) rapid test device was used with capillary and venous blood samples, relating it to the venous glycemic dosage. The analysis of the results showed a significant difference between the venous glucose dosage and the two methods used in the rapid test, between capillary blood glucose and plasma venous glucose (r=0.6543) and between venous blood and plasma venous glucose (r=0.5038) (p®laboratory tests(17). De Cordova et al. (2009)(1) compared the blood glucose levels of patients using the glucometer method and laboratory measurements to measure their correlation and differences. The Accu-Chek Advantage< (Abott) obtained better results using capillary blood, even though the two devices had a strong correlation with laboratory tests (r ≥ 0.95)® (Roche) device obtained better results using venous blood, while the Optium Xceed® (Abott) devices and compared with the conventional laboratory venous plasma glucose, concluding that there were differences between the glucometers and the laboratory method, an overall mean blood glucose of 119.57 mg/dL, ranging from 74 to 285 mg/dL, a coefficient of variation of 7.10% in which the Accu-Chek Performa® (Roche) and Optium Xceed® 0.001). Studies carried out by Neves et al., (2016)(18) used the Accu-Chek Performance.
Laboratory methods use the glucose oxidase method, a spectrophotometric technique in which blood is analyzed through a 505nm red product, precisely determining the concentration of glucose in the sample(19,20). The laboratory quality control requirements recommended by RDC 302 make this methodology the “gold standard” for these tests.
With the technological evolution and expansion of start ups, new point-of-care equipment has been offered in the Brazilian and world markets(21-24). A star up in southern Brazil developed a rapid test reader using colorimetry and immunochromatography methods using artificial intelligence (A.I.) and “internet of things” principles, capable of performing several quick tests because they are agile, practical and quick (circular letter No. 4/2019/ SEI/GGTES/DIRE1/ANVISA process No. 25351.934427/201891). The equipment of this star up, is equipment available in several pharmacy chains that despite the guarantee and quality certification of the manufacturer, there are no scientific studies related to the technology of this equipment with other existing ones, which can cause insecurity and distrust in users and caregivers. The positive correlation analysis of the equipment with other methodologies could guarantee safety for the patient, the caregiver and guarantee the quality of the results of this new technology(18,25,26).
Based on these principles, the aim of this study is to analyze the correlation of blood glucose results from digital pulp using artificial intelligence equipment (EIA) and using a glucometer, with venous blood glucose by laboratory analysis (gold standard).
MATERIALS AND METHODS
Outline: This is an experimental, descriptive cross-sectional study through the analysis of glucose blood from digital pulp and venous blood using 3 different technologies: laboratory glucose oxidase method (gold standard), glucometer (HGT) and artificial intelligence equipment (EIA).
Casuistry: 20 individuals of both sexes, aged between 18 and 50 years were recruited for voluntary participation for the donation of digital pulp and venous blood samples. Healthy, fasting and non-fasting diabetic patients were included in order to obtain samples with the greatest possible glycemic fluctuation due to the analytical range of the methods.
Experimental Procedure: Following the manufacturers’ standards, the calibration of the HGT devices (Accu-Check – Roche) and artificial intelligence equipment (EIA) was carried out. Digital pulp blood samples were collected from the side of the ring finger of the patient’s non-dominant hand and immediately and simultaneously analyzed using a glucometer and artificial intelligence (EIA) equipment. For analysis in the EIA, a drop of blood was placed in a capsule with reagents and introduced into a reader connected to the internet; after the analysis, the results were sent to the central laboratory of the manufacturer and analyzed; after analysis and verification, the report was sent via an application on the patient’s cell phone. These determinations were carried out in the pharmaceutical establishment under real conditions of analysis.
Then, 5mL samples of venous blood were collected aseptically from the antecubital fossa of the volunteers and placed in a test tube with sodium fluoride (antiglycolytic agent); samples were centrifuged at 1500 rpm for 15 minutes; the plasma was extracted and placed in Eppendorff flasks to perform the biochemical glucose dosage. Glucose concentration was determined by endpoint assay by the glucose oxidase principle using commercial biochemical analysis kits (Labtest®) following the manufacturer’s recommendations. Internal (Qualitrol – Labtest®) and external (Controllab®) quality were applied for reliability of the method. The spectrophotometric analysis was carried out with the reading in a semi-automated Biosystems BTS350® spectrophotometer. The determinations were performed in duplicate and the means used for statistical analysis purposes.
Ethical Aspects: The results were gathered and compiled into
a worksheet. Prior to the statistical analysis, data preparation
was carried out, with the intention of detecting typing errors and
missing data (missing) that could compromise the analyses. The
results were transcribed to a worksheet followed by descriptive and
inferential statistical analysis to determine measures of central tendency (mean) and dispersion (standard deviation).
The normality of the sample was tested using the Shapiro-Wilk test. With a non-parametric distribution, a correlation analysis was carried out based on a process of rank comparison, by determining the Spearman correlation coefficient with a minimum significance level of p < 0.05.
From the compilation of the data, correlation analysis was carried out in comparison of ranks, which consists of ordering the elements that make up the two sets of values under analysis, then calculating the Spearman correlation coefficient. Results expressed in absolute numbers where:
• 0.9 positive or negative indicates a very strong correlation;
- 0.7 to 0.9 positive or negative indicates a strong correlation;
- 0.5 to 0.7 positive or negative indicates a moderate correlation;
- 0.3 to 0.5 positive or negative indicates a weak correlation;
- 0 to 0.3 positive or negative indicates a negligible correlation.
The Kruskal-Wallis test was used to compare the means of the different methods. For pairwise comparison of methods between samples, the Wilcoxon paired test was applied with a minimum significance level of p < 0.05.
Spearman’s correlation analysis performed between all types of tests shows that there is a strong and statistically significant positive correlation, indicating the compatibility of results regardless of the method applied.
Figure 1 shows the graphical representation of the distribution of results from the correlation analysis of glucose measurements by glucometer (HGT) and artificial intelligence equipment (EIA) showing a Spearman correlation coefficient (R²) equal to 0.847 with a strong positive correlation and statistically significant (p<0.001).
0 0 50 100 150 200 250 300 350
Glicose (mg/dL) HGT
FIGURE 1: Graphical analysis of the linear correlation by rank between glucose measurements by hemoglycotest (HGT), artificial intelligence equipment (EIA).
Figure 2 shows the graphical representation of the distribution of results from the correlation analysis of glucose measurements by hemoglycotest (HGT) and conventional laboratory measurements, presenting a Spearman correlation coefficient (R²) equal to 0.822 with a strong positive and statistically significant correlation (p<0.001).
Glicose (mg/dL) EIA
Statistical analysis of glucose results by different methodologies shows no significant difference by the Kruskal-Wallis test for non-parametric data. By choosing to carry out a study with a heterogeneous population to achieve low and high concentrations of glucose, it resulted in a high standard deviation that could interfere in the interpretation of this specific analysis. To resolve this bias, a paired analysis of the patient was performed using the Wilcoxon paired test for non-parametric data, which also showed no significant difference Figure 4.
220 200 180 160
FIGURE 4 – Mean glucose concentration determined by glucometer (HGT), artificial intelligence equipment (EIA) and conventional laboratory dosage. Results expressed as mean ± standard deviation
HGT Laboratório AIA
Figure 3 shows the graphical representation of the distribution
of the results of the correlation analysis of glucose measurements
by artificial intelligence equipment (EIA) and conventional laboratory measurements showing a Spearman correlation coefficient (R²) equal to 0.755 with a strong positive correlation and statistically significant (p<0.001).
The highest coefficient was the correlation between the HGT and the EIA (R² = 0.847) probably because the same digital pulp whole blood sample was used, while the laboratory dosage used the dosage in fluoridated venous blood plasma. Even with different samples, the correlation of the HGT with the laboratory (R² = 0.822) was higher when compared to the EIA and the laboratory (R2 = 0.755).
The present study shows a strong correlation between the methods, however the mean concentration of the EIA in comparison with the gold standard laboratory methods and glucometer showed, on average, 40% higher values, which can be determinant in the identification of a normoglycemic, pre-diabetic patient or diabetic.
Regulatory agencies, users and other health professionals should be aware of new devices and procedures in the medical field that can facilitate the diagnosis of diseases quickly and easily, however, the fact that laboratory tests tend to be safer and more accurate in their results.
Conflicts of Interests: The authors declare they have no competing interests
- De Cordova CMM, Valle JP, Yamanaka CN, et al. Determination of capillary and venous blood glucose with a glucometer versus laboratory measurement of plasma glucose. J Bras Patol Med Lab. 2009; 45(5): 379-84.
- Saldarriaga EM, Vodicka E, La Rosa S, et al. Point-of-care testing for anemia, diabetes, and hypertension: a pharmacy-based model in lima, peru. Ann Glob Heal. 2017; 83(2): 394-404.
- Keller DL. Lowering blood glucose without increasing mortality. Am J Med. 2014; 127(5): e25.
- Schmidt AM. Highlighting diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018; 38(1): 1-8.
- Rigla M, Garcia-Saez G, Pons B, et al. Artificial intelligence methodologies and their application to diabetes. J Diabetes Sci Technol. 2018; 12(2): 303-10.
- Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2015; 22(4): 277-82.
- Horwich TB, Fonarow GC. Glucose, Obesity, Metabolic Syndrome, and Diabetes. Relevance to Incidence of Heart Failure. J Am Coll Cardiol. 2010; 55(4): 283-93.
- Nair AA, Velagapudi M, Behara L, et al. Hyper-G: An artificial intelligence tool for optimal decision-making and management of blood glucose levels in surgery patients. Methods Inf Med. 2019; 58(3): 79-85.
- Schnell O, Crocker JB, Weng J. Impact of hba1c testing at point of care on diabetes management. J Diabetes Sci Technol. 2017; 11(3): 611-7.
- Lisi F, Peterson JR, Gooding JJ. The application of personal glucose meters as universal point-of-care diagnostic tools. Biosens Bioelectron. 2020;Narla SN, Jones M, Hermayer KL, et al. Critical Care Glucose Point-of-Care Testing. 1st ed. Advances in Clinical Chemistry. Elsevier Inc. 2016; 76: 97-121.148: 111835.
- Steuten LMG, Kip M, Hooijdonk R, et al. Economic evaluation of blood glucose point-of-care testing in the intensive care unit. Value Heal. 2014;Melmer A, Laimer M. Treatment goals in diabetes. Endocr Dev. 2016; 31: 1-27.17(3): A250.
- Goble JA, Rocafort PT. Point-of-care testing: Future of chronic disease state management? J Pharm Pract. 2017; 30(2): 229-37.
- Li FF, Xie Y, Shi BY, et al. The real world of blood glucose point-of-care testing (POCT) system running in China teaching hospital. Expert Rev Med Devices. 2018; 15(6): 445-51.
- Larsson A, Greig-Pylypczuk R, Huisman A. The state of point-of-care testing: A European perspective. Ups J Med Sci. 2015; 120(1): 1-10.
- Kristensen T, Waldorff FB, Nexøe J, et al. Variation in point-of-care testing of HbA1c in diabetes care in general practice. Int J Environ Res Public Health. 2017; 14(11): 1-14.
- Neves RFB, Neves VM, Costa RR da, et al. Comparison between capillary and venous blood glucose measurements with glucometers and laboratory measurements of venous plasma glucose. Average Rev Minas Gerais. 2016; 26: 7.
- Rajendran R, Rayman G. Point-of-care blood glucose testing for diabetes care in hospitalized patients: An evidence-based review. J Diabetes Sci Technol. 2014; 8(6): 1081-90.
- Sobolesky PM, Smith BE, Saenger AK, Schulz K, Apple FS, Scott MG, et al. Multicenter assessment of a hemoglobin A1c point-of-care device for diagnosis of diabetes mellitus. Clin Biochem. 2018; 61:18-22.
- Foerster V, Severn M. Point-of-care glycated hemoglobin testing to diagnose type 2 diabetes. CADTH Issues Emerg Heal Technol. 2016; 1-8.
- Ellahham S. Artificial Intelligence: The Future for Diabetes Care. Am J Med. 2020; 133(8): 895-900.
- Shibata Y, Himeno T, Kamiya T, et al. Validity and reliability of a point-of-care nerve conduction device in diabetes patients. J Diabetes Investig. 2019; 10(5): 1291-8.
- Dankwa-Mullan I, Rivo M, Sepulveda M, et al. Transforming diabetes care through artificial intelligence: the future is here. Popul Health Manag. 2019; 22(3): 229-42.
- Shahim B, Kjellstrom B, Gyberg V, et al. The Accuracy of point-of-care equipment for glucose measurement in screening for dysglycemia in patients with coronary artery disease. Diabetes Technol Ther. 2018; 20(9): 596-602.
- Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018; 2(10): 719-31.